Heartbeam partners with evolve manufacturing to build heartbeam aimigotm 12-lead 3d vector electrocardiogram device

Santa clara, calif.--( business wire )--heartbeam, inc. (nasdaq: beat), a cardiac technology company that has developed the first and only 3d-vector electrocardiogram (vecg) platform for heart attack detection anytime, anywhere, today announced it has signed an agreement (the “agreement”) with evolve manufacturing technologies (“evolve”), a contract medical device manufacturing company, to build the credit card-sized aimigo 3d vector electrocardiogram (vecg) recording device that provides a 12 lead ecg readout for remote heart attack detection. under the terms of the agreement, heartbeam will leverage evolve's manufacturing and packaging expertise to support commercialization of the heartbeam aimigo device in anticipation of early market testing in q2 2023 following expected fda clearance in early 2023.
BEAT Ratings Summary
BEAT Quant Ranking